NASDAQ:XFOR
X4 Pharmaceuticals Inc. Stock News
$0.93
-0.0313 (-3.26%)
At Close: May 17, 2024
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
10:21am, Thursday, 21'st Jul 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Verve Therapeutics, Vertex Join Forces For Liver Disease-Focused Gene Program Vertex Pharmaceuticals I
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones
08:10pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Friday, 01'st Jul 2022 GlobeNewswire Inc.
BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients w
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
11:52pm, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wit
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor
10:05am, Monday, 16'th May 2022 GlobeNewswire Inc.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with r
X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q1 2022 Results - Earnings Call Transcript
12:53pm, Thursday, 12'th May 2022
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Schulman - Vice President, Investor Relations and Corporate Communications P
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
11:15am, Thursday, 12'th May 2022 Zacks Investment Research
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
10:05am, Thursday, 12'th May 2022 GlobeNewswire Inc.
Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
08:17am, Thursday, 12'th May 2022
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
10:05am, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wit
X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022
06:05am, Tuesday, 03'rd May 2022
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients wi
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
05:05pm, Friday, 08'th Apr 2022 GlobeNewswire Inc.
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wi
